Group items tagged

"18 645 patients with a total cholesterol of 6·5 mmol/L or greater were recruited from local physicians throughout Japan between 1996 and 1999. Patients were randomly assigned to receive either 1800 mg of EPA daily with statin (EPA group; n=9326) or statin only (controls; n=9319) with a 5-year follow-up. The primary endpoint was any major coronary event, including sudden cardiac death, fatal and non-fatal myocardial infarction, and other non-fatal events including unstable angina pectoris, angioplasty, stenting, or coronary artery bypass grafting. Analysis was by intention-to-treat. Findings At mean follow-up of 4·6 years, we detected the primary endpoint in 262 (2·8%) patients in the EPA group and 324 (3·5%) in controls-a 19% relative reduction in major coronary events (p=0·011). Post-treatment LDL cholesterol concentrations decreased 25%, from 4·7 mmol/L in both groups. Serum LDL cholesterol was not a significant factor in a reduction of risk for major coronary events. Unstable angina and non-fatal coronary events were also significantly reduced in the EPA group. Sudden cardiac death and coronary death did not differ between groups. In patients with a history of coronary artery disease who were given EPA treatment, major coronary events were reduced by 19% (secondary prevention subgroup: 158 [8·7%] in the EPA group vs 197 [10·7%] in the control group; p=0·048). In patients with no history of coronary artery disease, EPA treatment reduced major coronary events by 18%, but this finding was not significant (104 [1·4%] in the EPA group vs 127 [1·7%] in the control group; p=0·132)."

"Nov 14, 2005 | Michael O'Riordan. Dallas, TX - The addition of eicosapentaenoic acid (EPA) to low-dose statin therapy significantly reduced the incidence of major coronary events, largely driven by a reduction in unstable angina, when compared with patients taking statins alone. A subgroup analysis of the study, which involved a large number of primary-prevention patients, revealed that statin-treated secondary-prevention patients gained the most benefit from fish-oil supplementation. Dr Mitsuhiro Yokoyama Presenting the results of the Japan EPA Lipid Intervention Study (JELIS) during the late-breaking clinical-trials session at the American Heart Association Scientific Sessions 2005, Dr Mitsuhiro Yokoyama (Kobe University Graduate School of Medicine, Japan) said that the mechanism of benefit with EPA, a seafood-based, long-chain, n-3 polyunsaturated fatty acid, appears to be unrelated to the effects of cholesterol lowering. Commenting on the results of the study for heartwire, Dr Lawrence Appel (Johns Hopkins University School of Medicine, Baltimore, MD) said the findings are impressive given that the benefit of fish oil was observed on top of a regimen of statin therapy. He added that there are still some unknowns about which patient population would benefit most from fish oil."

"The Japan eicosapentaenoic acid (EPA) Lipid Intervention Study (JELIS) is a clinical trial that all Track Your Plaquers should know about. This enormous trial followed a simple design: Japanese men, between 40-75 years, and Japanese postmenopausal women aged

Cardio Defend™ Only $49/bottle - Limited Time Offer Flat Sale ONLY For Today - Special Offer Save Upto $120 + Special 71% Discount + 180 Day Money Back Guarantee CardioDefend Cardio Defend Rated FDA Approved CardioDefend Rated 5 Star Order TODAY And Save Up To $120! Save Over 71%! Cardio Defend is a dietary supplement that supports a healthy heart naturally. The lifestyle of individuals has evolved drastically, and with this evolution, mankind has seen a rise in individuals suffering from heart-related diseases. It supports healthy blood circulation and reduces blood pressure & the risk of heart disease naturally. Try CardioDefend For Over 71% OFF Today! Regular Price: $147.99/per bottle Only for: $49/per bottle Buy Cardio Defend Proven By Thousands Shannon Curry Mark Angelman Robert S Why Choose Cardio Defend? Made In The USA Made In The USA CardioDefend is manufactured on US soil. Cardio Defend 100% All Natural 100% All Natural All ingredients are pure, natural, and carefully sourced. FDA Approved Facility FDA Approved Facility CardioDefend is manufactured according to the latest standards. CardioDefend Supplement Cardio Defend Facts What is Cardio Defend? Heart disease is one of the top causes of death in the United States, but consumers continue to forgo the nourishment that they need. Even with all of the opportunities to eat better and exercise more, some people still struggle to improve their blood circulation and improve their heart health. Luckily, formulas like Cardio Defend can help a lot. CardioDefend is a dietary supplement that supports a healthy heart naturally. The lifestyle of individuals has evolved drastically, and with this evolution, mankind has seen a rise in individuals suffering from heart-related diseases. Even though exercise and healthy diets may help to reduce the risk of these conditions, they may not be 100% effective. The heart is an extremely important organ and must be taken good care of. CardioDefend naturally supports healt

Prevention of sudden cardiac death with omega-3 fatty acids in patients with coronary heart disease: A meta-analysis of randomized controlled trials.\nZhao YT, Chen Q, Sun YX, Li XB, Zhang P, Xu Y, Guo JH.\nAnn Med. 2009 Jan 16:1-10. [Epub ahead of print]\nPMID: 19148838

Arginine: Clinical potential of a semi-essential amino. Appleton J. Altern Med Rev. 2002 Dec;7(6):512-22. Review. PMID: 12495375